Skip to main content
Conference posters 2026

Explore our work

Explore a selection of our poster presentations from ISPOR 2026, showcasing innovative research, RWE, HEOR, and market access insights. Discover how our scientific expertise and integrated approach help generate evidence that informs healthcare decision-making and supports improved patient outcomes.

lightbulb and computer
Organizational Practices

US Payer Current and Future Adoption of Artificial Intelligence

AI is no longer just something US payers are talking about. It’s something they’re actively building into how they work.

Our team was pleased to present “US Payer Current and Future Adoption of Artificial Intelligence.” Our research at ISPOR on how payers are using AI today and where adoption is headed next. What stands out most is that AI use is already gaining traction in areas like prior authorization, population health analytics, claims processing, fraud detection, and member engagement, with even broader use expected over the next 3 years.

As payer AI capabilities mature, the way organizations generate evidence, communicate value, and engage with payer stakeholders will need to evolve too. Strong data, governance, and operational readiness will be critical.

Download full case study
Oncology
Oncology

The Institute for Clinical and Economic Review (ICER) Assessment Approaches to Survival
Extrapolation: A Review and Case Study

Looking back and pressure-testing the assumptions behind oncology cost-effectiveness evaluations.

This poster reviews how ICER selected survival-extrapolation curves across oncology assessments between 2016 and 2025. Re-analyzing the 2021 ide-cel multiple myeloma assessment with a broader set of candidate models produced life-year estimates approximately 30% lower than ICER’s selected log-normal curve (2.3 vs. 3.3 LYs), highlighting how survival-curve selection can materially shape cost-effectiveness conclusions.

The findings reinforce a central idea: in oncology HEOR, the methodological choices behind a cost-effectiveness estimate are not merely technical details—they shape the evidence that payers, regulators, and patients ultimately see.

Download full case study

A Modular Oncology Reference Model for Early Economic Evaluation:
A Case Study in EGFR-Mutated NSCLC

Information coming soon..

Download full case study
Methodological & Statistical Research

The False Confidence of Unanchored MAICs: Lessons in Ulcerative Colitis

Information coming soon..

Download full case study
Health Technology Assessment

Early perspectives on health technology assessment in the Kingdom of Saudi Arabia: exploratory survey into market access implications

Information coming soon..

Download full case study
Organizational Practices

US Payer Perspectives on Drug Manufacturer Readiness for Artificial Intelligence

Information coming soon..

Download full case study

Have a question for the authors or would like to discuss our experience with different indications or studies?

Get in touch

Headquarters:

HOBOKEN
111 River Street, Suite 1120
Hoboken, New Jersey 07030, US